STOCK TITAN
  1. Home
  2. Sec-filings
  3. FWBI
  4. [8-K] First Wave BioPharma, Inc. Common Stock Reports Material Event

[8-K] First Wave BioPharma, Inc. Common Stock Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock FWBI logo
First Wave BioPharma, Inc.

NASDAQ:FWBI

FWBI Rankings

#10156 Ranked by Market Cap
N/A Ranked by Dividends

FWBI Latest News

May 16, 2024
First Wave BioPharma Changes Name to Entero Therapeutics
May 10, 2024
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
May 9, 2024
First Wave BioPharma and Celiac Journey to Host Nasdaq Event in Support of Celiac Disease Awareness Month
Apr 24, 2024
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
Apr 17, 2024
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase

FWBI Latest SEC Filings

Jul 8, 2025
[8-K] First Wave BioPharma, Inc. Common Stock Reports Material Event
Jul 2, 2025
[S-1/A] First Wave BioPharma, Inc. Common Stock Amends IPO Registration Statement
Jul 2, 2025
[8-K] First Wave BioPharma, Inc. Common Stock Reports Material Event
Jun 30, 2025
[8-K] First Wave BioPharma, Inc. Common Stock Reports Material Event
Jun 23, 2025
[S-1/A] First Wave BioPharma, Inc. Common Stock Amends IPO Registration Statement

FWBI Stock Data

5.99M
2.75M
5.66%
1.46%
2.3%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOCA RATON